Iron Metabolism and Its Detection Through MRI in Parkinsonian Disorders: a Systematic Review

Overview

Journal Neurol Sci

Specialty Neurology

Date 2017 Sep 4

PMID 28866787

Citations 20

Authors

Sara Pietracupa

Antonio Martin-Bastida

Paola Piccini

Affiliations

Soon will be listed here.

Abstract

Iron deposition in the brain normally increase with age, but its accumulation in certain regions is observed in a number of neurodegenerative diseases including Parkinson's disease (PD) and other parkinsonisms. Whether iron overload leads to dopaminergic neuronal death in the SN of PD patients or is instead simply a by-product of the neurodegenerative progression is still yet to be ascertained. Magnetic resonance imaging (MRI) is a non-invasive method to assess brain iron content in PD patients. In PD, accurate radiologic visualization of basal ganglia is required. Deep gray matter nuclei are well presented in T2- and T2*-weighted images. T2*-weighted gradient-echo (GRE) is widely used to assess calcifications and also for iron detection. On the other hand, new methods specifically designed for detecting iron-induced susceptibility differences can be further improved by sequences like susceptibility-weighted imaging (SWI). In the present review, we aim to summarize the available data on brain iron deposition in PD.

Citing Articles

Review of the Brain's Behaviour after Injury and Disease for Its Application in an Agent-Based Model (ABM).

Irastorza-Valera L, Soria-Gomez E, Benitez J, Montans F, Saucedo-Mora L Biomimetics (Basel). 2024; 9(6).

PMID: 38921242 PMC: 11202129. DOI: 10.3390/biomimetics9060362.

Correlation of brain iron deposition and freezing of gait in Parkinson's disease: a cross-sectional study.

Yan Y, Wang Z, Wei W, Yang Z, Guo L, Wang Z Quant Imaging Med Surg. 2023; 13(12):7961-7972.

PMID: 38106290 PMC: 10721991. DOI: 10.21037/qims-23-267.

Application and progress of transcranial substantial ultrasound in Parkinson's disease.

Ma X, Li T, Du L, Han T Front Neurol. 2022; 13:1091895.

PMID: 36530621 PMC: 9751692. DOI: 10.3389/fneur.2022.1091895.

An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders.

Tambasco N, Nigro P, Chiappiniello A, Paoletti F, Scialpi S, Simoni S Behav Neurol. 2022; 2022:3972173.

PMID: 35251368 PMC: 8894064. DOI: 10.1155/2022/3972173.

Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease.

Lee J, Martin-Bastida A, Murueta-Goyena A, Gabilondo I, Cuenca N, Piccini P Nat Rev Neurol. 2022; 18(4):203-220.

PMID: 35177849 DOI: 10.1038/s41582-022-00618-9.

References

Drayer B, Olanow W, Burger P, Johnson G, Herfkens R, Riederer S . Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology. 1986; 159(2):493-8. DOI: 10.1148/radiology.159.2.3961182. View

Fasano M, Bergamasco B, Lopiano L . Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem. 2006; 96(4):909-16. DOI: 10.1111/j.1471-4159.2005.03638.x. View

Hare D, Double K . Iron and dopamine: a toxic couple. Brain. 2016; 139(Pt 4):1026-35. DOI: 10.1093/brain/aww022. View

Zecca L, Casella L, Albertini A, Bellei C, Zucca F, Engelen M . Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem. 2008; 106(4):1866-75. DOI: 10.1111/j.1471-4159.2008.05541.x. View

Hopes L, Grolez G, Moreau C, Lopes R, Ryckewaert G, Carriere N . Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?. PLoS One. 2016; 11(4):e0147947. PMC: 4818028. DOI: 10.1371/journal.pone.0147947. View

Lotfipour A, Wharton S, Schwarz S, Gontu V, Schafer A, Peters A . High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging. 2011; 35(1):48-55. DOI: 10.1002/jmri.22752. View

Crompton D, Chinnery P, Fey C, Curtis A, Morris C, Kierstan J . Neuroferritinopathy: a window on the role of iron in neurodegeneration. Blood Cells Mol Dis. 2003; 29(3):522-31. DOI: 10.1006/bcmd.2002.0589. View

Schwarz S, Afzal M, Morgan P, Bajaj N, Gowland P, Auer D . The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One. 2014; 9(4):e93814. PMC: 3977922. DOI: 10.1371/journal.pone.0093814. View

Wallis L, Paley M, Graham J, Grunewald R, Wignall E, Joy H . MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging. 2008; 28(5):1061-7. DOI: 10.1002/jmri.21563. View

10.

Zhang W, Sun S, Jiang Y, Qiao X, Sun X, Wu Y . Determination of brain iron content in patients with Parkinson's disease using magnetic susceptibility imaging. Neurosci Bull. 2009; 25(6):353-60. PMC: 5552500. DOI: 10.1007/s12264-009-0225-8. View

11.

Ayton S, Lei P, Bush A . Metallostasis in Alzheimer's disease. Free Radic Biol Med. 2012; 62:76-89. DOI: 10.1016/j.freeradbiomed.2012.10.558. View

12.

Miyoshi F, Ogawa T, Kitao S, Kitayama M, Shinohara Y, Takasugi M . Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy. AJNR Am J Neuroradiol. 2013; 34(11):2113-8. PMC: 7964843. DOI: 10.3174/ajnr.A3567. View

13.

Youdim M, Stephenson G, Ben Shachar D . Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci. 2004; 1012:306-25. DOI: 10.1196/annals.1306.025. View

14.

McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H . The neurological presentation of ceruloplasmin gene mutations. Eur Neurol. 2008; 60(4):200-5. DOI: 10.1159/000148691. View

15.

Devos D, Moreau C, Devedjian J, Kluza J, Petrault M, Laloux C . Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal. 2013; 21(2):195-210. PMC: 4060813. DOI: 10.1089/ars.2013.5593. View

16.

Bartzokis G, Cummings J, Markham C, Marmarelis P, TRECIOKAS L, Tishler T . MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging. 1999; 17(2):213-22. DOI: 10.1016/s0730-725x(98)00155-6. View

17.

Mugler 3rd J, Bao S, Mulkern R, Guttmann C, Robertson R, Jolesz F . Optimized single-slab three-dimensional spin-echo MR imaging of the brain. Radiology. 2000; 216(3):891-9. DOI: 10.1148/radiology.216.3.r00au46891. View

18.

Peckham M, Dashtipour K, Holshouser B, Kani C, Boscanin A, Kani K . Novel Pattern of Iron Deposition in the Fascicula Nigrale in Patients with Parkinson's Disease: A Pilot Study. Radiol Res Pract. 2016; 2016:9305018. PMC: 4947660. DOI: 10.1155/2016/9305018. View

19.

Reimao S, Ferreira S, Nunes R, Pita Lobo P, Neutel D, Abreu D . Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease. Eur J Neurol. 2015; 23(2):368-74. DOI: 10.1111/ene.12838. View

20.

Bastos Leite A, van Straaten E, Scheltens P, Lycklama G, Barkhof F . Thalamic lesions in vascular dementia: low sensitivity of fluid-attenuated inversion recovery (FLAIR) imaging. Stroke. 2004; 35(2):415-9. DOI: 10.1161/01.STR.0000109226.67085.5A. View